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Abstract
Orexin is a neuropeptide secreted from the lateral hypothalamus and prefrontal 
cortex concerned in wakefulness and excitement. This study aimed to review the pos-
sible neurobiological effect of orexin. A diversity of search strategies was adopted and 
assumed which included electronic database searches of Medline and PubMed using 
MeSH terms, keywords, and title words. Orexin plays a vital role in activation of learn-
ing, memory acquisition, and consolidation through activation of the monoaminergic 
system, which affects cognitive flexibility and cognitive function. Orexin stimulates 
adrenocorticotrophin (ACTH) and corticosteroid secretions via activation of the cen-
tral corticotropin-releasing hormone (CRH). Cerebrospinal (CSF) and serum orexin 
serum levels are reduced in depression, schizophrenia, and narcolepsy. However, high 
orexin serum levels are revealed in drug addictions. Regarding neurodegenerative 
brain diseases, CSF and serum orexin levels are reduced in Parkinson’s disease (PD), 
Alzheimer’s disease (AD), Huntington’s disease (HD), amyotrophic lateral sclerosis 
(ALS), and multiple sclerosis (MS). Orexin antagonist leads to significant reduction 
of sympathetic overactivity during withdrawal syndrome. Also, orexin antagonist 
improves sleep pattern. The orexinergic system is involved in different psychiatric and 
neurological disorders; therefore targeting of this system could be a possible novel 
pathway in the management of these disorders. In addition measurement of CSF and 
serum orexin levels might predict the relapse and withdrawal of addict patients.
Keywords: orexin, sleep disorders, psychiatric disorders, neurodegenerative 
disorders
1. Introduction
Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, 
wakefulness, and appetite. The most common form of narcolepsy, in which the 
sufferer experiences brief losses of muscle tone (cataplexy), is caused by a lack of 
orexin in the brain due to destruction of the cells that produce it. There are only 
10,000–20,000 orexin-producing neurons in the human brain, located predomi-
nantly in the perifornical area and lateral hypothalamus. They project widely 
throughout the central nervous system, regulating wakefulness, feeding, and other 
behaviors. The orexin system was initially suggested to be primarily involved in 
the stimulation of food intake, based on the finding that central administration of 
orexin-A and orexin-B increased food intake. In addition, it stimulates wakefulness, 
regulates energy expenditure, and modulates visceral function [1, 2].
Weight Management
2
Two distinct types of orexin, orexin-A and orexin-B, were identified; they act 
on specific receptors called orexin receptor type 1 (OX1R) and orexin receptor type 
2 (OX2R). Orexin-A activates both of these receptors equally, while orexin-B has 
a five times higher affinity to OX2R than OX1R. Upon activation, prepro-orexin 
will split to orexin-A and orexin-B, which act on their G protein-coupled receptors 
(Figure 1) [3].
Orexin receptors are distributed mainly in the lateral hypothalamus and adjacent 
areas, and their nerve fibers project to multiple brain regions. Orexinergic neurons 
in the lateral hypothalamus group are closely associated with reward-related func-
tions. These neurons preferentially innervate the ventral tegmental area and the 
ventromedial prefrontal cortex. In contrast, the perifornical-dorsal group of orex-
inergic neurons is involved in functions related to arousal and autonomic response. 
These neurons project inter-hypothalamically, as well as to the brainstem, where 
the release of orexin modulates various autonomic processes. Indeed, accumulating 
evidence shows that the orexin/receptor system is ectopically expressed in several 
neurological disorders, suggesting that it plays an important role in the incidence 
and pathogenesis of these diseases [4].
It has been verified that hypothalamic orexigenic neurons are involved in reward 
functions, while prefrontal orexigenic neurons are linked in the regulation of auto-
nomic and arousal functions. Moreover, orexin provokes and stimulates food intake 
via inhibition of autonomic digestive feedbacks. Orexigenic neurons are inhibited 
by leptin and food intake, while hypoglycemia and ghrelin activate orexigenic neu-
rons. Amino acid and high-protein diets paradoxically provoke the hyperpolariza-
tion of orexigenic neurons and block glucose-induced orexigenic neuron activations 
[5]. Animal model studies have shown that orexin is a very important link between 
sleep and body metabolism since sleep deprivation leads to higher food intake and 
induction of catabolism [6].
Additionally, orexin stimulates different neurotransmitters which are linked 
to the activation of the central nervous system, including acetylcholine, hista-
mine, noradrenaline, and dopamine. Therefore, mutations of orexin receptors 
lead to sleep disorders. Mice with orexin knockout are subjected to narcolepsy 
and excessive daytime sleepiness [7]. Alizamini et al. study showed that central 
Figure 1. 
Schematic representation of orexin system.
3Orexin and Psychoneurobiology: A Hidden Treasure
DOI: http://dx.doi.org/10.5772/intechopen.91852
administration of orexin leads to stimulation of locomotion, psychomotor perfor-
mance, body temperature, and energy expenditure. Furthermore, mice with orexin 
deficiency are subjected to obesity due to reduction of basal metabolic and energy 
expenditure rates. Beside, orexin knockout out mice is characterized by a reduction 
in brown adipose tissue thermogenesis with poor differentiation of pre-adipocyte 
into adipocytes in the adipose tissue [8]. Central and peripheral effects of orexin are 
illustrated in Figure 2.
The aim of this study was to provide a narrative review of the neurobiological 
effect of orexin system and to examine the association between orexin neuro-
transmission and different psychoneurological disorders, including depression, 
schizophrenia, addiction, Parkinson’s disease, and dementia. Evidence from experi-
mental, preclinical and clinical studies is evaluated for bidirectional relationships 
between orexin neurobiology and psychoneurological disorders. Given the nature 
of the subject area, it remains clear that this literature search cannot be regarded as 
a systemic review.
2. Method and search strategy
A diversity of search strategies was adopted and assumed which included 
electronic database searches of Medline and PubMed using MeSH terms, keywords, 
and title words. There is no limitation for publication year. The terms used for these 
searches were as follows: [orexin OR hypocretin] AND [cognitive function OR 
vigilance OR depression OR schizophrenia OR addiction OR Alzheimer dementia 
OR stroke OR sleep disorders]. [suvorexant OR orexin antagonists] AND [sleep 
disorders OR vigilance OR depression OR schizophrenia OR addiction]. Reference 
lists of identified and notorious articles were reviewed. Besides, only English 
articles were considered, and case reports were not involved in the review. The key 
Figure 2. 
Central and peripheral effects of orexin.
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features of recognized relevant search studies were considered, and the conclusions 
were summarized in a narrative review.
2.1 Orexin and cognitive function
Orexin regulates behavioral and neuroendocrine response during stressful con-
ditions as these events lead to the impairment of cognitive flexibility and function. 
Also, patients with psychiatric disorders such as panic disorder are associated with 
significant reduction of hypothalamic orexin activations [9].
It has been shown that stress improves male cognitive flexibility, but it 
worsens female cognitive flexibility due to gender differences in stress-induced 
orexin neuropeptide activations. Women are twice as likely as men to suffer 
from stress-related psychiatric disorders, such as post-traumatic stress disorder 
(PTSD) and major depressive disorder (MDD); however, the biological basis of 
these sex differences is not fully understood. Interestingly, orexins are known 
to be dysregulated in these disorders. Both preclinical and clinical studies 
have reported higher orexin system expression in females, which contributes 
to exaggerated neuroendocrine and behavioral responses to stress. Therefore, 
orexins may be important in the etiology of stress-related psychiatric disorders 
that present differently in men and women [10]. Piantadosi et al. illustrated 
that stimulation of prefrontal cholinergic neurons leads to the release of orexin 
from hypothalamic neurons, which play an important role in cognitive activa-
tion since high orexin activates the arousal state and executive functions via 
activation of cortical cholinergic neurons [11]. Chieffi et al. study reported the 
beneficial effects of exercise in stimulation of orexin release due to enhance-
ment of hippocampal activity as exercise attenuates hippocampal deteriora-
tion and depressive symptoms in elderly persons through regulation of orexin 
release [12].
Notably, cognitive impairment is the main feature of neurological and neuro-
psychiatric disorders as in dementia and narcolepsy, which are linked to orexin 
dysfunction. Therefore, intranasal orexin peptide may be an effective agent for 
cognitive dysfunction [13]. Astonishingly, orexin plays a crucial role in activation 
of learning and memory, as orexin-A provokes memory acquisition and consolida-
tion through activation of monoaminergic system. Consequently, orexin antagonist 
leads to significant memory dysfunction in the experimental rats [14]. Kim et al. 
study revealed that orexin is an important key factor of hippocampal neurogenesis 
as orexin-A participates in the hippocampal neuronal proliferation and neuropro-
tection following stroke; thus orexin agonist participates in prevention of negative 
stroke outcomes [15]. On the other hand, Uslaner et al. exhibited that dual orexin 
receptor antagonists (DORA-22) is an effective sedative agent, with less cogni-
tive disability than GABA allosteric modulators, which cause significant cognitive 
dysfunctions [16, 17]. Therefore, orexin improves cognitive functions as illustrated 
in different human and animal studies (Table 1).
2.2 Orexin and neuroendocrinology
Orexin is involved in the regulation of central and peripheral signals to regulate 
metabolic homeostasis. Alongside, orexin stimulates adrenocorticotrophin (ACTH) 
and corticosteroid secretions via activation of central corticotropin-releasing hor-
mone (CRH) and vasopressin. Therefore, orexin through OX2R receptor controls 
the hypothalamic-pituitary-adrenal axis (HPA) [18]. Previously, Malendowicz 
et al. illustrated that chronic orexin administration led to dose-dependent increase 
in cortisol and aldosterone plasma levels independent of ACTH levels, indicating a 
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direct stimulating effect of orexin on the adrenal cortex [19]. But in spite of these 
findings, Patel et al. study confirmed insignificant effect of orexin antagonists 
on ACTH and cortisol serum levels as well as on the markers of the sympathetic 
nervous system [20].
It has been reported that orexin administration leads to significant suppression 
of the hypothalamic prolactin release, which is not upturned by dopamine recep-
tor antagonists like metoclopramide suggesting a novel pathway in controlling of 
prolactin secretion. The mechanism of prolactin inhibition may be through inhibi-
tion of prolactin-releasing factor or stimulation of prolactin-inhibiting factor. But 
previous study illustrated insignificant effect of orexin antagonist on prolactin 
plasma levels [21, 22].
Many studies showed that the blood glucose is regulated by central orexin 
through regulation of hepatic glucose production, skeletal glucose consumption and 
thermogenesis. High orexin or dysrhythmic in orexin secretion is linked with the 
development of obesity and insulin resistance [23, 24]. Thus, suvorexant and other 
orexin antagonists are effective in the management of obesity and insulin resistance 
via amelioration of body adiposity and augmentation of energy expenditure that 
improve glucose metabolism. Moreover, orexin-A has important roles in the regula-
tion of pancreatic islet biology through activation of insulin secretion and prolonga-
tion of pancreatic islets life span [25].
Tsuneki et al. study illustrated that suvorexant improves glucose tolerance 
through inhibition of hepatic gluconeogenic factors, when administrated at resting 
time. However, administration of suvorexant at awaking time illustrates insignifi-
cant effect on glucose tolerance due to differential effects on the orexin sleep/wake 
operating system [26].
In addition, Flores et al. study illustrated an interaction between endocan-
nabinoid and orexigenic neurons as there is a similarity between OX1R and CB1 
receptors with diffuse overlapping in the anatomical distribution of these neurons. 
Therefore, the pharmacological effect of cannabinoid may be through orexigenic 
receptors [27]. The neuroendocrine effects of orexin are summarized in Table 2.
2.3 Orexin and psychiatric disorders
2.3.1 Orexin and depression
Among important etiological factors involved in the pathophysiology of depres-
sion, disturbances of monoamines and HPA are the main mechanistic pathways 
Species Interventions Results References
Animals Stimulation of prefrontal 
cholinergic neurons
↑ orexin Piantadosi et al. 
[11]
Humans and 
animals
Exercise  
Orexin-A administration
↑ orexin  
Provokes memory acquisition 
and consolidation
Chieffi et al. 
[12]
Humans Intranasal orexin-A 
administration
Improve cognition Calva and Fadel 
[13]
Mice Orexin-A administration Stimulates angiogenesis and 
neuroprotection
Kim et al. [15]
Humans Administration of orexin 
receptor antagonists
Stimulates angiogenesis and 
neuroprotection
Uslaner et al. 
[16]
Table 1. 
Orexin and cognitive functions.
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leading to functional disorders of neuroplasticity, which is regarded as a cardinal 
step in the onset of depression [28].
Diurnal variation in orexin serum levels revealed that high orexin levels are 
occurring at the middle of night. It has been reported that orexin level is signifi-
cantly decreased in patients with depression in comparison with healthy subjects 
[29]. But paradoxical high orexin serum levels are seen in some depressed patients, 
which is normalized by selective serotonin reuptake inhibitors. Since, orexin-A CSF 
levels are negatively correlated with depressive symptoms [30].
Long-term antidepressant agents improve orexin serum levels regardless of the 
type of antidepressant medications [31]. Nevertheless, there are different findings 
concerning orexin levels in depression. Feng et al. reported that depression is linked 
to reduction of serotonergic neuronal activity which is responsible for modulation 
of orexinergic activity [32]. Thus reduction of serotonergic neuronal activity leads 
to activation of orexin neuroactivity leading to depression. However, orexin levels 
are significantly reduced in depression compared with healthy control [33].
The initial animal model study observed reduction in the orexinergic neurons by 
18% with diminution in size of these neurons in comparison with normal rats. As 
well, prepro-orexin mRNA expression and orexin-A were reduced compared with 
control [34].
Previous preclinical study revealed a strong connection between low orexin 
and risk of depression which are inconsistent with previous studies that illustrated 
hypoactivity of orexinergic neurons in patients with depression since short-term 
antidepressant therapy improves sleep pattern through increasing and decreasing 
the expression of mRNA of orexin-A and orexin-B, respectively [35].
Ito et al. showed that administration of orexin-A leads to significant reduction 
of despair behavior in depression with important hippocampal neurogenesis via 
upregulation of neuropeptide Y (NPY). These changes are inhibited by co-adminis-
tration of orexin-A antagonist [36].
Therefore, orexin levels are different according to the pathophysiology of 
depression. Low orexin in depressed patients is associated with hypersomnia, 
whereas high orexin in depressed patients is associated with insomnia and inter-
rupted sleep [17]. Ji et al. illustrated that orexinergic neurons have direct connection 
to the ventral pallidum (VP) which is concerned with stress response and rewarding 
system. Orexin stimulates the VP and prevents depressive behavior. Therefore, 
high orexin in the VP is associated with elevated serum corticosterone serum levels 
Species Interventions Results References
Animals Orexin administration ↑ ACTH, cortisol Czerwinska et al. [18]
Animals Orexin administration ↑ cortisol, aldosterone Malendowicz et al. [19]
Humans Orexin administration No effect on ACTH 
and cortisol
Patel et al. [20]
Humans and 
animals
Orexin administration Inhibits prolactin Lyons et al. [21], Samson 
et al. [22]
Humans High orexin levels Insulin resistance and 
obesity
Gupta et al. [23], Cigdem 
et al. [24]
Humans and 
animals
Orexin administration ↑ insulin secretion Mediavilla and Risco [25]
Animals Administration of orexin 
antagonists
Improves glucose 
tolerance
Tsuneki et al. [26]
Table 2. 
Neuroendocrine effects of orexin.
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during acute stress, which per se prevent a depressive reaction against stressful 
events through improvement of stress resilience [37].
2.3.2 Orexin and schizophrenia
The association between orexin and schizophrenia had not been previously 
explored precisely [38]. Clinical and preclinical findings proposed that orexin and 
orexin agonist are of great value and useful in treating cognitive deficit in schizo-
phrenia [39]. There are widespread connection and interaction between orexin and 
dopaminergic neurons in midbrain, thalamocortical region, and amygdala suggest-
ing the potential role of orexinergic neurons in schizophrenia [40].
Modafinil is an atypical dopamine reuptake inhibitor used in the treatment 
of narcolepsy and antipsychotic drug-induced sleep disorder (Figure 3) [41]. 
Modafinil has been revealed as a complement of drugs in therapy of schizophre-
nia, and it reduce negative symptoms with no effect on the positive symptoms. 
Modafinil improves locomotor and psychomotor performances through activation 
of orexinergic neurons [42].
Therefore, activations of orexinergic neurons by modafinil may be an imperative 
step for future antipsychotic medications. These findings document that dopami-
nergic agonists mainly at D1 and D2 receptors modify orexinergic neurotransmis-
sions [43]. Also, dopamine antagonists that cause weight gain lead to activation of 
orexin pathway, but dopamine antagonists which do not cause weight gain do not 
activate orexin pathway [44]. Nevertheless, amphetamine which indirectly activates 
dopamine leads to activation of orexinergic neurotransmission despite induction of 
weight loss. Moreover, clozapine activates only orexinergic neurons in the prefron-
tal cortex [45]. Similarly, orexin antagonists abolish olanzapine and haloperidol 
effect on midbrain dopaminergic neurons, suggesting that orexin is an important 
neurotransmitter mediates the action of antipsychotic drugs [46]. As well, Chen 
et al. illustrated that orexin-A is stimulated and upregulated by non-obesegenic 
antipsychotic drugs [47]. Also, the high orexin level in patients with schizophrenia 
treated with antipsychotic drugs is regarded as a protective factor against the devel-
opment and risk of drug-induced metabolic syndrome [48]. Furthermore, orexin 
agonist like modafinil ameliorates cognitive function, attention, and antipsychotic-
induced sedation.
2.3.3 Orexin and addiction
The orexinergic system has broad projections and connections to different brain 
area which are concerned with drug-induced neuro-adaptation, including midbrain 
dopaminergic neurons, ventral tegmental area (VTA), nucleus accumbens (NA), 
Figure 3. 
Chemical structure of modafinil.
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amygdala, and medial prefrontal cortex (mPFC). Drug abuse leads to augmenta-
tion of dopaminergic activity in NA through activation of orexinergic neurons at 
mesocorticolimbic pathway [49]. Correspondingly, experimental studies illustrated 
that OX1R and OX2R are highly expressed in the NA leading to inhibitory effect 
instead of excitatory effects seen on the VTA, amygdala, and mPFC. Therefore, a 
differential effect of orexin is receptor type dependent [50].
Acute administration of addicting drugs such as methamphetamine, nico-
tine, and amphetamine leads to activation of orexinergic neurons at the lateral 
hypothalamus. However, acute administration of cocaine and morphine does not 
affect orexinergic neurons. Besides, chronic administration of addict drugs causes 
activation of orexinergic neurons mainly at OX2R receptors, but chronic increasing 
dose of addict drugs leads to downregulation of orexinergic receptors [51]. Carr 
and Kalivas reported that orexin is an important mediator which enables cocaine 
to induce addiction-like behavior in rats due to dopaminergic neuronal changes 
[52]. Also, James et al. verified that orexinergic neurons at the lateral hypothalamus 
play a vital role in expression of addiction-like phenotype [53]. Thus, the orexin-
ergic system is regarded as an important novel target for drug therapies to treat 
addiction.
Orexin serum level in chronic smoker subjects is related to craving in the phase 
of abstinence since it increased during addiction phase and reduced during with-
drawal phase. This reduction leads to increase in craving and risk of relapse [54]. 
Therefore, orexin serum level is regarded as a potential biomarker predicts time and 
risk of smoking relapse.
Furthermore, Tsai and Huang reported that the orexin serum level is increased 
in heroin addicts who shifted to methadone maintenance therapy compared with 
controls suggesting that methadone increases orexin serum levels [55]. Similarly, 
orexin serum level is increased in chronic alcoholism, which is positively correlated 
with the severity of alcohol withdrawal. Alleviation of alcohol withdrawal syn-
drome is linked with reduction of the orexin serum level, which monitors the status 
of alcoholic patients during the abstinence period [56].
2.3.4 Orexin and sleep disorders
Narcolepsy is a sleep disorder that causes excessive daytime sleepiness or an 
intractable urge to sleep in, in which duration of rapid eye movement sleep (REM) 
is reduced. Cataplexy is a sudden reduction in muscle tones with preserved con-
sciousness. Narcolepsy is commonly associated with cataplexy, which is triggered 
by emotional stimuli [57]. Methylphenidate, modafinil, and other psychostimulants 
are effective in the management of these sleep disorders [58]. Dysregulation of 
NREM sleep leads to narcolepsy only, whereas dysregulation of REM sleep leads to 
combined narcolepsy with cataplexy [59]. It has been reported that orexin increases 
vigilance through increasing awaking time and decreasing REM and NREM sleep 
periods. Both OX1R and OX2R are involved in the maintenance of arousal state 
directly or indirectly through the activation of monoaminergic neurons (nor-
adrenalin, dopamine, histamine, and serotonin). Also, orexin activates cholinergic 
neurons in the basal forebrain, which is also important for arousal statues [60]. 
Yamanaka et al. study illustrated that activation of OX2R by orexin leads to wake-
fulness which is mediated by a histamine neurotransmitter since antihistamine 
blocks the excitatory effect of orexin, while activation of OX1R by orexin leads to 
wakefulness, through noradrenalin neurotransmitter [61]. Reduction of orexin 
level in the cerebrospinal fluid was documented in patients with narcolepsy and 
nowadays is regarded as one of the diagnostic criteria in the diagnosis of narcolepsy. 
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Likewise, human postmortem study found that orexin peptide and prepro-orexin 
mRNA are deficient in the pons and cerebral cortex [62]. Therefore, these findings 
unveil that orexin is an important neuropeptide in the regulation of sleep and con-
solidated wakefulness. Table 3 summarized the potential role of orexin in common 
psychiatric disorders.
2.4 Orexin in neurodegenerative diseases
2.4.1 Parkinson’s disease
Orexinergic neurons are severely affected in Parkinson’s disease (PD); previ-
ously Fronczek et al. confirmed that orexinergic neuron density was reduced in 
the prefrontal cortex by 40% with significant reduction in CSF orexin levels in PD 
patients compared to the healthy control [63].
Furthermore, animal model study illustrated that 15% damage to the orexin-
ergic neurons did not affect CSF orexin, while damage more than 70% leads to 
50% decline in the CSF orexin [64]. These findings may explain the association of 
narcolepsy with PD since both dopamine and orexin interplay in the regulation of 
sleep pattern through activation of midbrain and thalamocortical pathway [65]. 
Feng et al. illustrated that in PD, there is a deficiency in hypoxia inducible factor 1 
alpha (HIF1-α) due to mitochondrial dysfunction and the administration of orexin-
A leads to significant neuroprotective effect on the dopaminergic neurons through 
the activation of HIF-α [66].
Moreover, orexin-A improves dopaminergic neurons in PD through the reduc-
tion of tyrosine hydroxylase (TH) and activation of brain-derived neurotrophic 
factor (BDNF) in the substantia nigra [43]. Therefore, orexin antagonist may 
increase risk of PD due to reduction of the neuroprotective and stimulating effects 
on the dopaminergic neurons at substantia nigra [67]. Sheng et al. found that 
orexin plays important roles in activation of the subthalamic nucleus which may 
give a new evidence for the participation of the subthalamic orexinergic system 
in PD. Importantly, orexin-A increased the protein level of brain-derived neuro-
trophic factor in dopaminergic neurons of the substantia nigra. The upregulation 
of BDNF is mainly via OX1R [68]. Long-term therapy with ropinirole in PD leads to 
significant reduction in the orexin activity which might explain the adverse effect 
of ropinirole-induced sleep disorder through inhibition of glutamatergic excitatory 
effect on the orexinergic neurons. Therefore, pharmacotherapy of PD should be 
re-evaluated in this context [69].
Psychiatric disorders Species Orexin levels References
Depression Human Decreased Kok et al. [29]
Human Increased Grady et al. [30]
Schizophrenia Human Decreased Mereu et al. [42]
Patel et al. [20]
Chronic smoking Animals Increased Al’Absi et al. [54]
Drug addictions Human Increased James et al. [53]
Alcoholism Human Increased Pan et al. [56]
Narcolepsy Human Decreased Gabelle et al. [62]
Table 3. 
Orexin and psychiatric disorders.
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2.4.2 Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disease affecting different brain 
areas characterized by cognitive deficit and progressive memory loss [70]. AD also 
affects hypothalamic orexinergic neurons leading to excessive daytime sleepiness, 
which is correlated with low orexin CSF levels, as reduction 40% of the brain cell 
number is linked with a 14% reduction in orexin CSF levels [71]. Normally, orexin 
regulates cholinergic and monoaminergic neuron firing during sleep and wakeful-
ness. In AD a reduction in the cholinergic pathway leads to disturbance in sleep 
patterns leading to daytime sleepiness and insomnia at night which are a hallmark 
of sleep rhythm in AD [72]. Besides, reduction of cholinergic activity causes overac-
tivity of orexinergic neurons, which causes abnormal sleep and cognitive functions. 
These changes lead to an elevation of the orexin CSF level, which is linked with 
reduced REM sleep [73].
Dementia with Lewy bodies is characterized by an elevation in α-synuclein level, 
which is accumulated in orexin-containing neurons at the hypothalamus caus-
ing interference in orexin axonal transport. This effect leads to a reduction in the 
activity of the orexinergic system in dementia with Lewy bodies but not in AD [74]. 
Therefore, there are complexities in the orexinergic system according to the clinical 
presentation and sleep pattern in patients with AD.
2.4.3 Huntington’s disease
Huntington’s disease (HD) is a hereditary neurodegenerative disorder 
characterized by personality changes, motor disturbances, cognitive decline, 
and weight loss [75]. HD is caused by a defect in the gene encoding huntingtin, 
a protein with unclear function, which is essential for cell survival during 
development and in adult life [76]. In HD there is neurodegeneration involving 
the neostriatum and cerebral cortex, with the manifestation of intraneuronal 
aggregates of misfolded huntingtin. Moreover, in patients with end-stage HD, 
there is about 90% of neuronal loss in the tuber nucleus of the lateral hypo-
thalamus. Orexin-A and orexin-B are synthesized from the same precursor 
gene and are expressed in the same neurons with their cell bodies concentrated 
to the lateral hypothalamus [77]. Preclinical and clinical studies observed 
that orexin serum and CSF levels are decreased by 72% in HD. In healthy 
subjects, orexin CSF level is >200pg/ml, but in HD and narcolepsy, this level is 
decreased below 110 pg/ml, due to degeneration of orexinergic neurons in the 
lateral hypothalamus. Therefore, CSF orexin level is regarded as a biomarker to 
evaluate the disease progression and usefulness of therapeutic intervention in 
patients with HD [78, 79]. However, Meier et al. illustrated that CSF and serum 
orexin levels are of no diagnostic value in prediction and follow-up of  
HD [80].
Recently, Cabanas et al. observed that orexin in HD has aberrant effects leading 
to abnormal sleep pattern, and thus orexin antagonist suvorexant may be of great 
value in restoring normal sleep and behavioral disturbance in HD [81] in addition, 
these neurons remain functional and illustrate paradoxical effect, it become more 
modifiable and affect by serotonine and noradrenaline, and less sensitive to the 
effect of suprachiasmatic nucleus (the master clock of the brain) causing abnormal 
biological circadian rhythm [81, 82].
Therefore, orexin level in HD is reduced, but the remaining functional orex-
inergic neurons lead to abnormal circadian biological rhythm causing behavioral, 
motor, and sleep disturbances.
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2.4.4 Multiple sclerosis
Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers 
of nerve cells in the brain and spinal cord are damaged. This damage disrupts the 
ability of parts of the nervous system to transmit signals, resulting in a range of 
signs and symptoms, including physical, mental, and sometimes psychiatric prob-
lems. Specific symptoms can include double vision, blindness in one eye, muscle 
weakness, and trouble with sensation or coordination. MS takes several forms, with 
new symptoms either occurring in isolated attacks (relapsing forms) or building up 
over time (progressive forms). Between attacks, symptoms may disappear com-
pletely; however, permanent neurological problems often remain, especially with 
the advancement of the disease [83, 84].
The three main characteristics of MS are the formation of lesions in the central 
nervous system, inflammation, and the destruction of myelin sheaths of neurons. 
These features interact in a complex and not yet fully understood manner to 
produce the breakdown of nerve tissue and in turn the signs and symptoms of the 
disease. Cholesterol crystals are believed to both impair myelin repair and aggravate 
inflammation. MS is believed to be an immune-mediated disorder that develops 
from an interaction of the individual’s genetics and as yet unidentified environmen-
tal causes. Damage is believed to be caused, at least in part, by attack on the nervous 
system by a person’s own immune system [85].
Considering the multiplicity of symptoms associated with multiple sclerosis 
(MS), there is possibility that hypocretin system function might be involved in 
the pathogenesis of the disease. Papuc et al. showed that high orexin CSF level in 
patients with MS as compared with healthy controls, but it positively correlated 
with fatigue level, suggesting a compensatory mechanism for the production of 
orexin in MS [86]. On the other hand, Nozaki et al. illustrated that orexin CSF level 
is reduced and correlated with symmetrical hypothalamic lesion and spinal cord 
damage in MS. Therefore, low orexin level was implicated in the pathogenesis of 
hypersomnia and cognitive deficit in patients with MS [87]. Recently, Pallais et al. 
confirmed that orexin has a neuroprotective effect in MS through inhibition of 
inflammatory and proinflammatory mediators mainly matrixmetaloproteinases 
(MMP-3, MMP-9) which are involved in damage of neuronal matrix proteins. 
Consequently, low CSF orexin level indicates underlying active disease [88].
Therefore, CSF orexin level is a valuable biomarker in the diagnosis and predic-
tion of the severity of MS.
2.4.5 Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease 
(MND), is a disease that leads the death of neurons controlling voluntary muscles. 
The underlying mechanism involves damage to both upper and lower motor 
neurons. ALS is characterized by stiff muscles, muscle twitching, and muscle 
weakness is still unknown. The cause of ALS is not known in 90% of cases but is 
believed to involve both genetic and environmental factors. The remaining 10% of 
cases is inherited [89]. Previously, Van Rooij et al. illustrated that CSF orexin level 
was normal in patients with ALS and not correlated with age and gender. However, 
a disturbance in the orexinergic system is involved in the pathogenesis of ALS [90]. 
Moreover, the pathogenesis of ALS is associated with lateral hypothalamic lesions, a 
site of the orexinergic system leading to sleep disturbances and hypersomnia [91].
Despite different and large body of literature survey, little is known about CSF 
orexin levels, in clinical and preclinical studies in ALS.
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Therefore, orexin CSF level and orexinergic activity in different neurodegenera-
tive diseases are summarized in Table 4.
2.5 Orexin antagonists and neurobiology
Regarding orexin antagonists, suvorexant is a dual orexin receptor antagonist 
was approved by the Food and Drug Administration (FDA) on 13 August 2014 [92]. 
Other orexin antagonists are almorexant, lemborexant, and filorexant are used in 
the management of insomnia and other sleep disorders. Also, these drugs may be of 
great value in the control of depressive disorders and peripheral diabetic neuropa-
thy [93].
Suvorexant (Figure 2) is the first orexin antagonists approved in the United States 
for treatment of insomnia, which is effective in reduction of time to sleep onset and 
increase of total sleeping time [94]. Moreover, administration of SB-33867 which 
is an orexin antagonist leads to significant reduction of sympathetic tone causing a 
reduction in blood pressure, heart rate, and plasma noradrenalin. These findings sug-
gest that orexin through OX1 receptor regulates sympathetic tone since intravenous 
administration of orexin leads to parallel increases in noradrenalin plasma levels [95].
Hatta et al. study confirmed the significant effect of suvorexant in the manage-
ment of delirium in elderly patients in acute care units. The anti-delirium effect is 
due to the regulation of circadian biology [96]. Delirium is proposed to be related of 
suvorexant to disturbances and disorders in sleep pattern in critically ill patients in 
the intensive care unit. Also, attention disorders are caused by disturbances in the 
ascending reticular activating system (ARAS) which is responsible for maintenance of 
human arousal. Normally, the arousal state is regulated and stimulated by ARAS neu-
rotransmitters and by hypothalamic orexin [97]. Therefore, orexin receptor antago-
nists may play important role in the regulation of hypothalamic and brain stem stress 
during acute injury. Moreover, a recent study by Kawada et al. illustrated that suvorex-
ant add-on therapy to ramelteon in the management of sleep disorders in patients with 
acute stroke is more effective than when combined with benzodiazepines [98].
It has been verified that prolonged alcohol consumption is associated with 
sleep disturbance which is a powerful factor for relapse and setback to alcohol use. 
Suvorexant reduces the motivation properties of alcohol, so it plays a crucial role in 
the prevention of alcoholism [99].
Beside, Gentile et al. study revealed the possible role of suvorexant in reduction 
of motor impulsivity of cocaine-induced psychostimulant effects. Thus suvorexant 
may be effective in attenuation of cocaine withdrawal syndrome [100].
As well, suvorexant had placebo-like effect on EEG in comparison with zolpidem 
which has a significant reduction in the spectral density of rapid eye movement and 
non-rapid eye movement sleep (NREM) pattern [101].
Psychiatric disorders Species CSF orexin levels References
Parkinson’s disease Human Decreased Fronczek et al. [63]
Alzheimer’s disease Human Increased Liguori et al. [73]
Huntington’s disease Human Decreased Mignot et al. [78]
Animals Normal Papuc et al. [86]
Multiple sclerosis Human Decreased Nozaki et al. [87]
ALS Human Normal Van Rooij et al. [90]
Table 4. 
Orexin and neurodegenerative diseases.
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In spite of the wide uses of suvorexant in the management of sleep disorders and 
controlling insomnia, it did not reduce the psychomotor performances as docu-
mented by Vermeeren et al. study [102].
Orexin-A is involved in regulation of feeding; it stimulates nocturnal feeding 
through OX1 receptor. Therefore, OX1 receptor antagonist regulates feeding and 
reduced nocturnal feeding; thus, orexin antagonist could be useful in the treatment 
of obesity [103]. Orexin-A is implicated in the pathogenesis of obesity; it promotes 
hyperphagia through central activation of cannabinoid receptors and inhibition 
of melanocyte-stimulating hormone [104]. Both orexin-A and endocannabinoid 
increases glucose response of neuronal excitability in the arcuate nucleus leading to 
induction of feeding and obesity [104].
In summary, more research is required to reinforce the extant information on 
the importance of the limited number of factors studied to date and provide data 
on additional potentially relevant effects. Similarly, rubric for such research should 
shift from preclinical and animal model studies to clinical studies to illustrate 
disease progression and treatment effects in relation to orexin neurobiology. This 
study suggests that orexin system is a future target in the management of different 
psychoneurological disorders after delineating the specific role of orexin receptor 
agonists and antagonists. Moreover, measurement of orexin serum level which is an 
easy method may be of great value in evaluation and assessment of different neuro-
logical disorders. Also, ratio of orexin serum level/CSF orexin level may reflect the 
activity of endogenous orexinergic system.
3. Conclusion
Orexin system is regarded as a potential novel target in the management of 
schizophrenia, depression, addiction, and sleep disorders. Orexin serum level might 
predict relapse and withdrawal of addict patients.
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